Safety confirmation study with dMD-003

Safety confirmation study with dMD-003 - Study to evaluate the safety of dMD-003 in patients scheduled to undergo uterine myomectomy -

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2072230083

Enrollment

Registered

2023-11-07

Start date

2024-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine leiomyoma

Interventions

The study device (dMD-003) is applied to the injury site of the uterus immediately before wound closure in uterine myomectomy.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Patients scheduled to undergo laparoscopic, laparoscopy-assisted, or open uterine myomectomy. Other criteria.

Exclusion criteria

Exclusion criteria: (1) Patients who have undergone surgery in the abdominal or pelvic cavity (excluding surgery for appendicitis). (2) Patients with concurrent active pelvic inflammatory disease or peritonitis. (3) Patients suspected of having moderate (stage III) or severe endometriosis according to the r-ASRM classification. Other criteria.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events up to 12 weeks after surgery.	—

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-3-3225-6303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026